next-gen
drug delivery platforms
at the right place
with the right therapy
at the right time​
to cure
the incurable
Our Vision
Chiromesh Therapeutics is an early-stage company engineering a novel, biodegradable, micro-structured and pliable film – µMESH (micro-mesh) – for the sustained delivery of various therapeutic agents, including chemotherapeutic drugs, small inhibitors, monoclonal antibodies, nanomedicines, and oncolytic viruses, targeting uncurable malignancies
​​​​​
µMESH has been validated for the treatment of high-grade gliomas, where localized and sustained delivery of advanced chemo-immunotherapies enhances therapeutic efficacy while avoiding systemic toxicity
High-Grade
Gliomas
High-grade gliomas (glioblastoma) are among the most aggressive tumors
With a 5-year survival rate of only 5% and no major advancements in clinical standard in over two decades, glioblastoma leaves patients with a life expectancy of less than 20 months
In the treatment of glioblastoma, even a modest increase in survival is considered a great success
5% survival at 5 years
median survival below 20 months
20,000+ US cases per year
Our Core Technology
µMESH against high-grade gliomas
µMESH is a micro-structured, flexible polymeric film capable of adhering to complex biological surfaces and delivering thereof a variety of therapeutic agents
​​​​​​
Like a surgical patch, the biodegradable and foldable µMESH is deposited at the tumor margins during routine surgical intervention for tumor resection
​​​​​
Through a single intracranial deposition, µMESH enables the local release of powerful combination therapies for days, weeks, and months
Precise micro-Structure
Using consolidated techniques from microchip manufacturing, µMESH is microfabricated to produce unique structures with micrometric accuracy and high reproducibility
Advanced Treatment Solutions
µMESH has two drug-compartments and can hold a variety of therapeutic payloads, and its architecture and composition remain consistent regardless of the payloads used
Reaching deep into the tumor
µMESH adheres and conforms to complex biological surfaces and establishes high drug concentration gradients right at the tumor margins, thus facilitating the uniform and deep permeation of various therapeutics agents
Personalized Care Approaches
µMESH is engineered to deliver small molecules, peptides, proteins, monoclonal antibodies, nanomedicines, and oncolytic viruses, enabling the administration of personalized therapeutic regimens to maximize efficacy for each patient
Key Technological Features
Discover how the technological advancements of µMESH provide precise control over disease progression and effectively combat high-grade gliomas and other uncurable malignancies with advanced therapies.
Precise micro-Structure for Sustained Drug Delivery
µMESH proprietary architecture accommodates a variety of payloads using well-known, FDA-approved synthetic and natural polymers. Its tunable degradation rates enable the sustained release of therapeutic agents from days, to weeks and months
Multi- Drug Compartment
µMESH comprises multiple drug compartments for the localized delivery of powerful combination therapies, including chemotherapies, targeted therapies, and immunotherapies. By enabling the the precise control of the spatial and temporal distribution of different therapeutic agents within the brain parenchyma, µMESH directly addresses major challenges in the treatment of aggressive brain tumors - poor brain penetrance, tumor heterogeneity, and systemic toxicity
Mechanical Flexibility
The customizable geometry and mechanical properties of µMESH, including adjustable pore sizes and strands' flexibility, enable it to conform precisely to complex biological surfaces like the tumor margins. The intimate contact with the surrounding malignant tissue ensures targeted drug delivery, maximizing therapeutic efficacy and minimizing off-target effects